Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.
about
The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domainTargeting SH2 domains in breast cancerSTATs in cancer inflammation and immunity: a leading role for STAT3STAT inhibitors for cancer therapy.A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3.Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies.Binding modes of peptidomimetics designed to inhibit STAT3.Progress towards the development of SH2 domain inhibitors.Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.DINC: a new AutoDock-based protocol for docking large ligands.Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer TherapeuticsTargeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity.Structure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 (Stat3).Extolling the benefits of molecular therapeutic lipidation.Design, synthesis, conformational analysis and application of indolizidin-2-one dipeptide mimics.Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic LiabilitiesIdentification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.Identification of a New Series of STAT3 Inhibitors by Virtual Screening.Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept.Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development.
P2860
Q26861758-2655569E-E429-4D07-B980-FE43D9BA5905Q27014674-776F7B15-D5CD-4C14-AB33-B89EC23ECB50Q29547203-D8963215-78E9-4BCE-9B3F-F14B0B890A9CQ33644206-52D7DFA2-CDF5-46C2-92B7-8635B8140BA4Q33661939-2C0797E5-DDA9-41F6-A2B9-76B411C548D2Q33718067-3CFBC0FF-0ABB-436B-9766-B1D0FA550857Q33811131-AE534B2C-7FDA-4CA8-901D-36B05EC58387Q34492859-F278214D-902C-4446-B9C0-55127D153584Q34516992-6B0030D7-5BD4-4FD8-9DCA-D3CCCF7D86F2Q34581878-E24EE62C-55E4-4039-8267-F74618B73633Q35000997-10AA1BA2-CD4F-42AE-9C4A-D4A559919859Q35030931-7F9E4BE3-6638-45B2-8EC6-1CAB748D7B5AQ35101950-F6F8EC03-4DB4-4295-B152-F7E1EDC43687Q35869426-40383733-D14F-426E-B956-52EBE0B94E3BQ36918125-33201808-9C29-449A-8CA6-27A94AD597EAQ37414868-DEE4EAEA-F4C3-48CF-86AF-5003AFF35780Q37683068-2B189A31-B399-42DB-9F0D-E1922C8ED183Q38114781-6A78A9EA-45A2-43CF-AC99-29486E8D1D61Q38217773-4E172610-00EA-4326-AAE0-ED60A30B677BQ38782370-D9D9317C-2F99-4F81-8A42-9079BC821613Q39159381-69F0C767-6E6C-450F-97AF-C89DC6E3DC22Q39159653-5B68CFDF-4C75-48AF-A1C3-5954D8D786E2Q39514656-8241BC6E-E411-4137-BFDB-E490DDF28E2BQ39685915-C5BDAD5B-3D72-4F77-9ABE-6AB9BBB0DBDAQ53436083-795DB464-E2BB-4270-A0BE-A97147C32902Q55637644-85E787DC-0177-4F08-B220-BEE2D87BD637
P2860
Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Conformationally constrained p ...... uation and molecular modeling.
@en
Conformationally constrained p ...... uation and molecular modeling.
@nl
type
label
Conformationally constrained p ...... uation and molecular modeling.
@en
Conformationally constrained p ...... uation and molecular modeling.
@nl
prefLabel
Conformationally constrained p ...... uation and molecular modeling.
@en
Conformationally constrained p ...... uation and molecular modeling.
@nl
P2093
P2860
P356
P1476
Conformationally constrained p ...... luation and molecular modeling
@en
P2093
Chiyi Xiong
David R Coleman
Donald Limbrick
Garrett A Dyer
J Sanderson Birtwistle
John S McMurray
Pijus K Mandal
Xiaomin Chen
Zhiyong Ren
P2860
P304
P356
10.1021/JM801491W
P407
P577
2009-04-01T00:00:00Z